Abstract
In patients (pts) with ALK+ NSCLC, resistance to the first-generation ALK TKI CRZ eventually develops, with CNS progression and/or ALK-acquired resistance mutations. ALC and BRG are CNS-active, next-generation ALK TKIs with differing selectivity vs these mutations. Single-arm post-CRZ trials with ALC reported median PFS (mPFS) <12 mo, while BRG showed mPFS >16 mo (16.3–16.7). ALTA-3 (NCT03596866) was designed to test whether BRG efficacy is superior to ALC in ALK+ NSCLC that progressed on CRZ. We report results of the preplanned interim analysis (IA).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
